Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients.
- Author:
Jing QIN
1
;
Peng-Hai ZHANG
;
Xin-Yu QIAN
;
Shi-Jun KANG
;
Rong-Cheng LUO
;
Yue-Gang WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; adverse effects; therapeutic use; Biomarkers, Tumor; blood; Carcinoma, Non-Small-Cell Lung; blood; drug therapy; Creatine Kinase, MB Form; blood; Endostatins; adverse effects; genetics; therapeutic use; Female; Humans; Lung Neoplasms; blood; drug therapy; Male; Middle Aged; Natriuretic Peptide, Brain; blood; Ovarian Neoplasms; blood; drug therapy; Peptide Fragments; blood; Recombinant Proteins; adverse effects; therapeutic use; Risk Assessment; Troponin T; blood
- From: Journal of Southern Medical University 2008;28(6):930-932
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the value of the myocardial biochemical markers including creatine kinase MB isoenzyme (CK-MB), cardiac isoform of Tropnin-T (cTnT) and N-termimal pro-brain natriuretic peptide (NT-proBNP) and electrocardiogram (ECG) in monitoring the cardiotoxicity of recombinant human endostatin (rh-endostatin) in cancer patients.
METHODSForty cancer patients were divided into two groups and received rh-endostatin in addition to chemotherapy (group A, n=24) or chemotherapy only (Group B, n=24). Serum CK-MB, cTnT levels and plasma NT-proBNP levels were measured and the ECG was recorded in all the patients before and after each of the two therapy cycles.
RESULTSIn group A, serum CK-MB, cTnT and plasma NT-proBNP levels were significantly increased after the treatment in comparison with the baseline levels (P<0.05), but such increment was not observed in group B (P>0.05). With comparable baseline levels of CK-MB, cTnT and NT-proBNP before the treatment (P>0.05), patients in group A showed significantly higher levels of the indices than those in group B after each therapy cycle (P<0.05). Increased ECG abnormality were observed after rh-endostatin treatment in Group A (P<0.05) at a rate significantly higher than that of Group B after the second treatment cycle (P<0.05).
CONCLUSIONRh-endostatin has definite cardiotoxicity, and detection of the myocardial biochemical markers of CK-MB, cTnT and NT-proBNP may help predict the occurrence of cardiotoxicity.
